Poly-Dtech
keyboard_backspaceBack to HomeContact
204 Avenue de Colmar
67100 Strasbourg
France
Président de Poly-Dtech
About us
Founded in 2019, Poly-Dtech is a company based in Strasbourg specializing in innovative solutions for biomarker detection thanks to a cutting-edge technology named Bright-Dtech. Our mission is to provide better detection to improve screening, drug discovery, and early diagnosis of diseases. The Bright-Dtech technology is the result of many years of work and collaboration between experts in nanoparticle synthesis, spectroscopy, biology, and analytical techniques (immunoassays) in France and internationally. Our multicultural team is made up of experts in various fields, notably in chemistry and biology applied to detection.
Business offer
Poly-Dtech develops and produces immunoassays based on high-performance fluorescent nanoparticles with unique features, offering enhanced detection sensitivity and user-friendly protocols for several techniques (TR-FRET, TR-FLISA, Lateral Flow, Multiplex).
Bright-Dtech & Link-Dtech Kits: Lanthanide nanoparticle kits for improved biomarker detection sensitivity and for low concentrations.
Assay Kits: Biomarker detection kits using the TR-FRET or TR-FLISA method (Human IgG, PSA, Trastuzumab, SARS-CoV-2)
Custom Assay Development: We develop custom assays for specific needs, offering improved sensitivity and excellent reproducibility (TR-FRET, TR-FLISA, Lateral Flow, Multiplex)
Activities
- Therapeutic Product
- Service
- Cardiology
- Genetic Diseases
- Oncology
- Infectiology
- Immunology
- Inflammation
- Target selection & validation
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Research exploratory companion biomarkers
- Preclinical biomarkers
- Research exploratory Companion biomarkers
- Animal biomarkers
- Human biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Clinical biomarkers
- Predictive biomarkers
- Treatment efficacy
- Disease progression / follow-up
- PK/PD features
- Surrogate markers
- Disease progression monitoring